Movement Alert｜Keymed Biosciences Rises 5.46% in Regular Trading, AbbVie USD 10.9 Billion Apogee Acquisition Continues to Catalyze Long-Acting AD Track Valuation

Market Focus

Jun 29

On June 29, Keymed Biosciences-B (02162.HK) rose 5.46% in regular trading, reaching HKD 70.05 per share, with turnover of HKD 119 million.

On the news front, AbbVie's previously announced plan to acquire Apogee Therapeutics for approximately USD 10.9 billion continues to validate multinational pharma's strategic conviction in long-acting atopic dermatitis assets. Apogee's core product is APG777, a long-acting IL-13 monoclonal antibody with dosing intervals extendable to 3-6 months. Keymed's CM512, an IL-13/TSLP bispecific antibody with a half-life of approximately 70 days, belongs to the same long-acting AD track and could similarly support extended dosing intervals, positioning it favorably in this revaluation cycle.

Additionally, the company has received a USD 257 million upfront payment from Gilead's acquisition of Ouro Medicines and a USD 45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, significantly strengthening its cash position and further clarifying its global value realization pathway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1193216623"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193216623\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193216623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193216623","market":"us","top_or_hot":-1,"title":"Movement Alert｜Keymed Biosciences Rises 5.46% in Regular Trading, AbbVie USD 10.9 Billion Apogee Acquisition Continues to Catalyze Long-Acting AD Track Valuation","media":"Market Focus","content":"<p><p>On June 29, Keymed Biosciences-B (02162.HK) rose 5.46% in regular trading, reaching HKD 70.05 per share, with turnover of HKD 119 million.</p><p>On the news front, AbbVie's previously announced plan to acquire Apogee Therapeutics for approximately USD 10.9 billion continues to validate multinational pharma's strategic conviction in long-acting atopic dermatitis assets. Apogee's core product is APG777, a long-acting IL-13 monoclonal antibody with dosing intervals extendable to 3-6 months. Keymed's CM512, an IL-13/TSLP bispecific antibody with a half-life of approximately 70 days, belongs to the same long-acting AD track and could similarly support extended dosing intervals, positioning it favorably in this revaluation cycle.</p><p>Additionally, the company has received a USD 257 million upfront payment from Gilead's acquisition of Ouro Medicines and a USD 45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, significantly strengthening its cash position and further clarifying its global value realization pathway.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Keymed Biosciences Rises 5.46% in Regular Trading, AbbVie USD 10.9 Billion Apogee Acquisition Continues to Catalyze Long-Acting AD Track Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Keymed Biosciences Rises 5.46% in Regular Trading, AbbVie USD 10.9 Billion Apogee Acquisition Continues to Catalyze Long-Acting AD Track Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-29 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 29, Keymed Biosciences-B (02162.HK) rose 5.46% in regular trading, reaching HKD 70.05 per share, with turnover of HKD 119 million.</p><p>On the news front, AbbVie's previously announced plan to acquire Apogee Therapeutics for approximately USD 10.9 billion continues to validate multinational pharma's strategic conviction in long-acting atopic dermatitis assets. Apogee's core product is APG777, a long-acting IL-13 monoclonal antibody with dosing intervals extendable to 3-6 months. Keymed's CM512, an IL-13/TSLP bispecific antibody with a half-life of approximately 70 days, belongs to the same long-acting AD track and could similarly support extended dosing intervals, positioning it favorably in this revaluation cycle.</p><p>Additionally, the company has received a USD 257 million upfront payment from Gilead's acquisition of Ouro Medicines and a USD 45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, significantly strengthening its cash position and further clarifying its global value realization pathway.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1193216623","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193216623","pubTimestamp":1782698600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 29, Keymed Biosciences-B (02162.HK) rose 5.46% in regular trading, reaching HKD 70.05 per share, with turnover of HKD 119 million.On the news front, AbbVie's previously announced plan to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"动静快讯|科亚医药常规盘涨5.46%艾伯维109亿美元收购Apogee持续催化长效广告赛道估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On June 29, Keymed Biosciences-B (02162.HK) rose 5.46% in regular trading, reaching HKD 70.05 per share, with turnover of HKD 119 million.On the news front, AbbVie's previously announced plan to acquire Apogee Therapeutics for approximately USD 10.9 billion continues to validate multinational pharma's strategic conviction in long-acting atopic dermatitis assets. Apogee's core product is APG777, a long-acting IL-13 monoclonal antibody with dosing intervals extendable to 3-6 months. Keymed's CM512, an IL-13/TSLP bispecific antibody with a half-life of approximately 70 days, belongs to the same long-acting AD track and could similarly support extended dosing intervals, positioning it favorably in this revaluation cycle.Additionally, the company has received a USD 257 million upfront payment from Gilead's acquisition of Ouro Medicines and a USD 45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, significantly strengthening its cash position and further clarifying its global value realization pathway.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}